Pfizer Inc. undefined and BioNTech SE undefined said results from an 'initial laboratory study' showed that their COVID-19 vaccine neutralized the omicron...
Pfizer Inc. PFE, +0.47% and BioNTech SE BNTX, +8.17% said results from an"initial laboratory study" showed that their COVID-19 vaccine neutralized the omicron variant of the coronavirus after three doses, or the full two-dose regimen plus a booster shot. The drug makers said those who received just two does of the vaccine showed, on average, a more than 25-fold reduction in neutralization against the omicron variant. The research is very preliminary.
The companies did not say how many people they gathered sera from, and it was released in a news release, not a preprint or peer-reviewed medical study."Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it's clear from these preliminary data that protection is improved with a third dose of our vaccine," said Pfizer Chief Executive Albert Bourla.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer, ex-employee reach accord over COVID-19 vaccine secretsPfizer Inc has reached a truce with a former longtime employee it sued two weeks ago for allegedly stealing confidential documents related to its COVID-19 vaccine and other drugs.
Baca lebih lajut »
Omicron significantly reduces Covid antibody protection in small study of Pfizer vaccine recipients
Baca lebih lajut »
Pfizer CEO says omicron appears milder but spreads faster and could lead to more Covid mutations
Baca lebih lajut »
Omicron variant partly evades Pfizer vaccine's protection, study showsThe Omicron coronavirus variant partly escapes the protection offered by the Pfizer vaccine, but people who have been previously infected and then vaccinated are likely to be well protected, researchers working in South Africa reported Tuesday.
Baca lebih lajut »
Pfizer vaccine 'partially protective' against OmicronOmicron variant of the coronavirus can partially evade the protection from Pfizer and partner BioNTech's vaccine, new research shows
Baca lebih lajut »